CGON - CG Oncology - Stock Price & Catalysts • BiopharmIQ

Enterprise Value

1.632B

Cash

566.5M

Avg Qtr Burn

-15.93M

Short % of Float

13.40%

Insider Ownership

7.05%

Institutional Own.

72.33%

Qtr Updated

03/31/24

Drug Pipeline

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.

Drug & Indication	Stage & Event	Catalyst Date
Cretostimogene Details Non-muscle invasive bladder cancer, Cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cretostimogene Details Non-muscle invasive bladder cancer, Cancer	Phase 3 Data readout	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cretostimogene + KEYTRUDA Details Non-muscle invasive bladder cancer, Cancer	Phase 2 Update	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.
Cretostimogene Details Non-muscle invasive bladder cancer, Cancer	Phase 2 Initiation	Some catalyst date You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details. You must sign up to see the catalyst details.Sign up now.